BRPI0409393A - composto, composição farmacêutica, e, métodos para modulação de atividade de receptor de quimiocina em um mamìfero, para tratamento, melhora, controle ou redução do risco de um distúrbio ou doença inflamatório e imunorregulatório, e de artrite reumatóide - Google Patents

composto, composição farmacêutica, e, métodos para modulação de atividade de receptor de quimiocina em um mamìfero, para tratamento, melhora, controle ou redução do risco de um distúrbio ou doença inflamatório e imunorregulatório, e de artrite reumatóide

Info

Publication number
BRPI0409393A
BRPI0409393A BRPI0409393-3A BRPI0409393A BRPI0409393A BR PI0409393 A BRPI0409393 A BR PI0409393A BR PI0409393 A BRPI0409393 A BR PI0409393A BR PI0409393 A BRPI0409393 A BR PI0409393A
Authority
BR
Brazil
Prior art keywords
rheumatoid arthritis
chemokine receptor
inflammatory
ameliorating
mammal
Prior art date
Application number
BRPI0409393-3A
Other languages
English (en)
Inventor
Stephen D Goble
Sander G Mills
Alexander Pasternak
Lihu Yang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0409393A publication Critical patent/BRPI0409393A/pt
Publication of BRPI0409393A8 publication Critical patent/BRPI0409393A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA MODULAçãO DE ATIVIDADE DE RECEPTOR DE QUIMIOCINA EM UM MAMìFERO PARA TRATAMENTO, MELHORA, CONTROLE OU REDUçãO DO RISCO DE UM DISTúRBIO OU DOENçA INFLAMATóRIO E IMUNORREGULATóRIO, E DE ARTRITE REUMATóIDE". Compostos ciclopentila ligados a um grupo benzoxazinila através de uma porção amido utilizando o nitrogênio de anel da benzoxazina e ainda substituído com uma porção heterocíclica, estes compostos representados pela fórmula (I), que são usados para modular o receptor de quimiocina CCR-2 para evitar ou tratar distúrbios e doenças inflamatórios e imunorregulatórios, doenças alérgicas, condições atópicas incluindo rinite alérgica, dermatite, conjuntivite, e asma, assim como patologias autoimunes, como artrite reumatóide e aterosclerose; e composições farmacêuticas compreendendo estes compostos e o uso destes compostos e composições.
BRPI0409393A 2003-04-15 2004-04-09 composto, composição farmacêutica, e, métodos para modulação de atividade de receptor de quimiocina em um mamífero, para tratamento, melhora, controle ou redução do risco de um distúrbio ou doença inflamatório e imunorregulatório, e de artrite reumatóide BRPI0409393A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46311103P 2003-04-15 2003-04-15
PCT/US2004/011281 WO2004092124A2 (en) 2003-04-15 2004-04-09 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors

Publications (2)

Publication Number Publication Date
BRPI0409393A true BRPI0409393A (pt) 2006-04-18
BRPI0409393A8 BRPI0409393A8 (pt) 2018-05-08

Family

ID=33300038

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409393A BRPI0409393A8 (pt) 2003-04-15 2004-04-09 composto, composição farmacêutica, e, métodos para modulação de atividade de receptor de quimiocina em um mamífero, para tratamento, melhora, controle ou redução do risco de um distúrbio ou doença inflamatório e imunorregulatório, e de artrite reumatóide

Country Status (23)

Country Link
US (1) US7700591B2 (pt)
EP (1) EP1615699B1 (pt)
JP (1) JP4440257B2 (pt)
KR (1) KR20060003353A (pt)
CN (1) CN1802187B (pt)
AT (1) ATE461929T1 (pt)
AU (1) AU2004231087B2 (pt)
BR (1) BRPI0409393A8 (pt)
CA (1) CA2521950C (pt)
CY (1) CY1110155T1 (pt)
DE (1) DE602004026166D1 (pt)
DK (1) DK1615699T3 (pt)
ES (1) ES2342776T3 (pt)
IS (1) IS8056A (pt)
MX (1) MXPA05011160A (pt)
NO (1) NO20055376L (pt)
NZ (1) NZ543287A (pt)
PL (1) PL1615699T3 (pt)
PT (1) PT1615699E (pt)
RU (1) RU2301802C2 (pt)
SI (1) SI1615699T1 (pt)
WO (1) WO2004092124A2 (pt)
ZA (1) ZA200507796B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1909906A (zh) * 2004-01-20 2007-02-07 默克公司 作为趋化因子受体活性调节剂的2,6－二取代的哌啶类化合物
US20070238723A1 (en) * 2004-10-15 2007-10-11 Goble Stephen D Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
US20080194548A1 (en) * 2005-01-06 2008-08-14 Forrest Michael J Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
BRPI0710512A2 (pt) * 2006-04-20 2012-06-05 Hoffmann La Roche moduladores derivados de diazepan de receptores de quimiocinas
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
WO2009068318A1 (en) * 2007-11-30 2009-06-04 Noxxon Pharma Ag Mcp-i binding nucleic acids and use thereof
KR100904535B1 (ko) * 2009-03-09 2009-06-29 한세이엔씨(주) 교량의 박스거더 내부 안전진단장치
CA2755697A1 (en) 2009-03-17 2010-09-23 Daiichi Sankyo Company, Limited Amide derivative
SG174463A1 (en) * 2009-04-07 2011-10-28 Astrazeneca Ab Isoxazol-3(2h)-one analogs as therapeutic agents
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
EP2534158B1 (en) 2010-02-09 2014-01-08 Bristol-Myers Squibb Company Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity
CN103694220A (zh) * 2013-12-30 2014-04-02 张磊 新型吡唑-3-甲酸酯及合成方法
RU2564440C1 (ru) * 2014-06-03 2015-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" 3-ароил-2-гидрокси-2-(2-оксоциклоалкил)пирроло[2,1-с][1,4]бензоксазин-1,4(2н)-дионы, проявляющие анальгетическую активность, и способ их получения
MX2017009314A (es) 2015-01-16 2017-11-08 Bayer Cropscience Ag Metodo para la preparacion de hidrocloruro de 4-cianopiperidina.
WO2016139165A1 (en) * 2015-03-05 2016-09-09 Bayer Cropscience Aktiengesellschaft Process for preparing piperidine-4-carbothioamide hydrochloride
RU2726206C2 (ru) 2015-05-21 2020-07-09 Кемосентрикс, Инк. Модуляторы ccr2
WO2017015376A1 (en) 2015-07-23 2017-01-26 Huntsman Advanced Materials Americas Llc Curable benzoxazine compositions
US11304952B2 (en) 2017-09-25 2022-04-19 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
EP3737367A4 (en) 2018-01-08 2022-11-09 ChemoCentryx, Inc. METHODS OF TREATING SOLID TUMORS USING CCR2 ANTAGONISTS
US11352357B2 (en) * 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
CN116730855B (zh) * 2023-08-08 2023-10-20 苏州开元民生科技股份有限公司 3-氨基-4-氯苯甲酸十六酯的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647804A (en) * 1970-02-27 1972-03-07 Upjohn Co Cycloalkanecarboxamides
US3772308A (en) * 1972-06-02 1973-11-13 Lilly Co Eli Cyclopentanecetamides and cyclopentaneacetonitriles
GB9812037D0 (en) 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
WO2000076512A1 (en) * 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US7166614B2 (en) * 2002-04-29 2007-01-23 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
CA2483752C (en) * 2002-04-29 2011-03-29 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2004110376A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Ccr-2 antagonists for treatment of neuropathic pain
US20070238723A1 (en) * 2004-10-15 2007-10-11 Goble Stephen D Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
US20080194548A1 (en) * 2005-01-06 2008-08-14 Forrest Michael J Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders

Also Published As

Publication number Publication date
US7700591B2 (en) 2010-04-20
BRPI0409393A8 (pt) 2018-05-08
CA2521950A1 (en) 2004-10-28
CY1110155T1 (el) 2015-01-14
RU2301802C2 (ru) 2007-06-27
ATE461929T1 (de) 2010-04-15
WO2004092124A2 (en) 2004-10-28
JP2006523702A (ja) 2006-10-19
EP1615699B1 (en) 2010-03-24
DK1615699T3 (da) 2010-07-19
SI1615699T1 (sl) 2010-07-30
IS8056A (is) 2005-09-29
US20060069088A1 (en) 2006-03-30
KR20060003353A (ko) 2006-01-10
EP1615699A4 (en) 2008-03-19
ES2342776T3 (es) 2010-07-14
CN1802187B (zh) 2011-09-14
RU2005135432A (ru) 2006-04-27
MXPA05011160A (es) 2005-12-14
JP4440257B2 (ja) 2010-03-24
NO20055376D0 (no) 2005-11-14
WO2004092124A8 (en) 2010-02-25
CN1802187A (zh) 2006-07-12
WO2004092124A3 (en) 2005-04-14
AU2004231087B2 (en) 2007-01-04
CA2521950C (en) 2009-11-17
AU2004231087A1 (en) 2004-10-28
NO20055376L (no) 2006-01-13
PT1615699E (pt) 2010-05-21
NZ543287A (en) 2008-08-29
ZA200507796B (en) 2007-02-28
PL1615699T3 (pl) 2010-08-31
DE602004026166D1 (de) 2010-05-06
EP1615699A2 (en) 2006-01-18

Similar Documents

Publication Publication Date Title
BRPI0409393A8 (pt) composto, composição farmacêutica, e, métodos para modulação de atividade de receptor de quimiocina em um mamífero, para tratamento, melhora, controle ou redução do risco de um distúrbio ou doença inflamatório e imunorregulatório, e de artrite reumatóide
EA200801934A1 (ru) 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2
NO20070484L (no) Sammenspleisede pyrimidinderivater og sammensetninger derav som CXCR3 reseptormodulatorer, anvendbare ved forebygging og behandling av inflammatoriske og immunregulatoriske lidelser og sykdommer.
MX2010003113A (es) Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina.
EA200700617A1 (ru) Новые пиридиновые производные и их применение в качестве позитивных аллостерических модуляторов mglur2-рецепторов
EA201000332A1 (ru) 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны
PT2139334E (pt) Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
WO2005105092A3 (en) 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity
EA201000331A1 (ru) 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны
UA84749C2 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
NO20076477L (no) Nye heterosykliske forbindelser som positive allosteriske modulatorer av metabotrope glutamatreseptorer
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
ATE478876T1 (de) Thienopyridine als allosterische verstärker des m4-muscarinrezeptors
BR0314059A (pt) Compostos heterocìclicos
GB0510584D0 (en) Organic compounds
DE602005023124D1 (de) Spirobenzodioxole und deren verwendung als cb1-antagonisten
DE602006017209D1 (de) Carbamat-derivate als positive allosterische modulatoren von metabotropischen glutamat-rezeptoren
EA201190301A1 (ru) ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
WO2005070133A3 (en) 2,6-disubstituted piperidines as modulators of chemokine receptor activity
WO2005120505A3 (en) Tetrahydropyranyl cyclopentyl tetrahy-dropyridopyridine modulators of chemokine receptor activity
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
DE602006010540D1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
EA200870591A1 (ru) 2-фенил-5-амино-1,3,4-оксадиазолы и их применение в качестве лигандов никотинового рецептора ацетилхолина
WO2005110409A3 (en) Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: NOME ALTERADO DE: MERCK AND CO., INC.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/55 (2006.01), A61P 29/00 (2006.01), A61K 3

B11T Dismissal of application maintained [chapter 11.20 patent gazette]